Amphipathic properties of HIV-1 gp41 fusion inhibitors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 24, 2011, Pages 3022-3032

  Gochin, Miriam ^a   Zhou, Guangyan ^b  

^a Touro University California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphiphilic; gp41; HIV 1; Hydrophobic pocket; Inhibition; Small molecules

Indexed keywords

4 (8 BETULINOYLAMINOOCTANOYLAMINO) 3 HYDROXY 6 METHYLHEPTANOIC ACID; ADSJ 1; AMPHOPHILE; ANTIRETROVIRUS AGENT; CATECHOL; CYCLOPEPTIDE; DETERGENT; DYE; EPIGALLOCATECHIN GALLATE; FLAVONOID; FORMAZAN; GALLOCATECHIN GALLATE; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 41 FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYBRID PROTEIN; HYDROXYTYROSOL; NATURAL PRODUCT; NB 179; NB 180; NB 214; NB 225; NB 228; NB 235; OLEUROPEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PALMITIC ACID; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; PF 68742; PLANT EXTRACT; POLYANION; POLYPHENOL DERIVATIVE; TANNIN; TIFUVIRTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XTT FORMAZAN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; CYTOTOXICITY; DRUG BINDING; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; IC 50; LIPID RAFT; LIPOPHILICITY; MEDIATOR; MOLECULAR DOCKING; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW; TEA; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN;

CELL MEMBRANE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; PEPTIDES; VIRUS INTERNALIZATION;

EID: 80054909887     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798808488     Document Type: Review

References (113)

1. Dorrucci, M. [Epidemiology of HIV. Update]. Recenti Prog. Med., 2010, 101 (1), 12-15.
2. Steffen, I.; Pohlmann, S. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr. Pharm. Des., 2010, 16 (9), 1143-1158.
3. Kim, J. H.; Rerks-Ngarm, S.; Excler, J. L.; Michael, N. L. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS, 2010, 5 (5), 428-434.
4. Groot, F.; Welsch, S.; Sattentau, Q. J. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood, 2008, 111(9), 4660-4663.
5. Markosyan, R. M.; Xiuwen, M.; Lu, M.; Cohen, F. S.; Melikyan, G. B. The Mechanism of Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Recombinant Cores of gp41 Ectodomain. Virology, 2002, 302, 174-184.
6. Eckert, D. M.; Kim, P. S. Mechanisms of Viral Membrane Fusion and Its Inhibition. Annual. Rev. Biochem., 2001, 70, 777-810.
7. Naider, F.; Anglister, J. Peptides in the treatment of AIDS. Curr. Opin. Struct. Biol., 2009, 19 (4), 473-482.
8. Eckert, D. M.; Shi, Y.; Kim, S.; Welch, B. D.; Kang, E.; Poff, E. S.; Kay, M. S. Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci. 2008, 17 (12), 2091-2100.
9. Champagne, K.; Shishido, A.; Root, M. J. Interactions of HIV-1 inhibitory peptide T20 with the GP41 N-HR coiled coil. J. Biol. Chem., 2008, 284(6),3619-3627
10. Steger, H. K.; Root, M. J. Kinetic dependence to HIV-1 entry inhibition. J. Biol. Chem., 2006, 281 (35), 25813-25821.
11. Kahle, K. M.; Steger, H. K.; Root, M. J. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog., 2009, 5 (11), e1000674.
12. Chan, D. C.; Chutkowski, C. T.; Kim, P. S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA, 1998, 95 (26), 15613-15617.
13. Jiang, S.; Zhao, Q.; Debnath, A. K. Peptide and non-peptide fusion inhibitors. Curr. Pharm. Des., 2002, 8, 563-580.
14. Liu, S.; Wu, S.; Jiang, S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr. Pharm. Des., 2007, 13 (2), 143-162.
15. Cai, L.; Jiang, S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem, 2010, 5 (11), 1813-1824.
16. Pan, C.; Liu, S.; Jiang, S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J. Formos Med. Assoc., 2010, 109 (2), 94-105.
17. Caffrey, M.; Cai, M.; Kaufman, J.; Stahl, S. J.; Wingfield, P. T.; Covell, D. G.; Gronenborn, A. M.; Clore, G. M. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J., 1998, 17 (16), 4572-4584.
18. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell, 1997, 89 (2), 263-273.
19. Gallo, S. A.; Puri, A.; Blumenthal, R. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process. Biochemistry (Mosc) 2001, 40 (41), 12231-12236.
20. Ferrer, M.; Kapoor, T. M.; Strassmaier, T.; Weissenhorn, W.; Skehel, J. J.; Oprian, D.; Schreiber, S. L.; Wiley, D. C.; Harrison, S. C. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements [see comments]. Nat. Struct. Biol., 1999, 6 (10), 953-960.
21. Weissenhorn, W.; Dessen, A.; Calder, L. J.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol., 1999, 16 (1), 3-9.
22. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. Inhibition of HIV-1 Infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein gp41. Biochem. Biophys. Res. Commun., 1993, 195, 533.
23. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. HIV-1 inhibition by a peptide. Nature, 1993, 365 (6442), 113.
24. Lu, M.; Kim, P. S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn., 1997, 15 (3), 465-471.
25. Wild, C.; Oas, T.; McDanal, C.; Bolognesi, D.; Matthews, T. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci., 1992, 89, 10537-10541.
26. Wild, C. T.; Greenwell, T.; Matthews, T. A synthetic peptide from gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retrovirus., 1993, 9, 1051-1053.
27. Kliger, Y.; Shai, Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J. Mol. Biol., 2000, 295 (2), 163-168.
28. Dwyer, J. J.; Wilson, K. L.; Davison, D. K.; Freel, S. A.; Seedorff, J. E.; Wring, S. A.; Tvermoes, N. A.; Matthews, T. J.; Greenberg, M. L.; Delmedico, M. K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. USA, 2007, 104 (31), 12772-12777.
29. Kilgore, N. R.; Salzwedel, K.; Reddick, M.; Allaway, G. P.; Wild, C. T. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J. Virology, 2003, 77 (13), 7669-7672.
30. He, Y.; Xiao, Y.; Song, H.; Liang, Q.; Ju, D.; Chen, X.; Lu, H.; Jing, W.; Jiang, S.; Zhang, L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem., 2008, 283 17), 11126-11134.
31. Shimura, K.; Nameki, D.; Kajiwara, K.; Watanabe, K.; Sakagami, Y.; Oishi, S.; Fujii, N.; Matsuoka, M.; Sarafianos, S. G.; Kodama, E. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J. Biol. Chem., 2010, 285(50),39471-39480
32. Gochin, M.; Cai, L. The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. J. Med. Chem., 2009, 52 (14), 4338-4344.
33. Horne, W. S.; Johnson, L. M.; Ketas, T. J.; Klasse, P. J.; Lu, M.; Moore, J. P.; Gellman, S. H. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc. Natl. Acad. Sci. USA, 2009, 106 (35), 14751-14756.
34. Sia, S. K.; Carr, P. A.; Cochran, A. G.; Malashkevich, V. N.; Kim, P. S. Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA, 2002, 99 (23), 14664-14669.
35. Wang, D.; Lu, M.; Arora, P. S. Inhibition of HIV-1 fusion by hydrogen-bond-surrogate-based alpha helices. Angew Chem. Int. Ed. Engl., 2008, 47 (10), 1879-1882.
36. Eggink, D.; Baldwin, C. E.; Deng, Y.; Langedijk, J. P.; Lu, M.; Sanders, R. W.; Berkhout, B. Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol., 2008, 82 (13), 6678-6688.
37. Eggink, D.; Langedijk, J. P.; Bonvin, A. M.; Deng, Y.; Lu, M.; Berkhout, B.; Sanders, R. W. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J. Biol. Chem., 2009, 284 (39), 26941-26950.
38. Veiga, A. S.; Santos, N. C.; Loura, L. M.; Fedorov, A.; Castanho, M. A. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J. Am. Chem. Soc., 2004, 126 (45), 14758-14763.
39. Franquelim, H. G.; Loura, L. M.; Santos, N. C.; Castanho, M. A. Sifuvirtide screens rigid membrane surfaces. establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J. Am. Chem. Soc., 2008, 130 (19), 6215-6223.
40. Liu, S.; Lu, H.; Niu, J.; Xu, Y.; Wu, S.; Jiang, S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem., 2005, 280 (12), 11259-11273.
41. Peisajovich, S. G.; Gallo, S. A.; Blumenthal, R.; Shai, Y. C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J. Biol. Chem., 2003, 278 (23), 21012-21017.
42. Wexler-Cohen, Y.; Shai, Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J., 2007, 21 (13), 3677-3684.
43. Lorizate, M.; de la Arada, I.; Huarte, N.; Sanchez-Martinez, S.; de la Torre, B. G.; Andreu, D.; Arrondo, J. L.; Nieva, J. L. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence. Biochemistry (Mosc), 2006, 45 (48), 14337-14346.
44. Lorizate, M.; Gomara, M. J.; de la Torre, B. G.; Andreu, D.; Nieva, J. L. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J. Mol. Biol., 2006, 360 (1), 45-55.
45. Bellamy-McIntyre, A. K.; Lay, C. S.; Baar, S.; Maerz, A. L.; Talbo, G. H.; Drummer, H. E.; Poumbourios, P. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J. Biol. Chem., 2007, 282 (32), 23104-23116.
46. Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y. J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T. J.; Moore, J. P.; Miller, M. D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. USA, 2009, 106 (14), 5801-5806.
47. Wexler-Cohen, Y.; Shai, Y. Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog., 2009, 5 (7), e1000509.
48. Pascual, R.; Moreno, M. R.; Villalain, J. A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism. J. Virol., 2005, 79 (8), 5142-5152.
49. Moreno, M. R.; Pascual, R.; Villalain, J. Identification of membrane-active regions of the HIV-1 envelope glycoprotein gp41 using a 15-mer gp41-peptide scan. Biochim. Biophys. Acta, 2004, 1661 (1), 97-105.
50. Lev, N.; Fridmann-Sirkis, Y.; Blank, L.; Bitler, A.; Epand, R. F.; Epand, R. M.; Shai, Y. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action. Biochemistry (Mosc,) 2009, 48 (14), 3166-3175.
51. Lev, N.; Shai, Y. Fatty acids can substitute the HIV fusion peptide in lipid merging and fusion: an analogy between viral and palmitoylated eukaryotic fusion proteins. J. Mol. Biol., 2007, 374 (1), 220-230.
52. Korazim, O.; Sackett, K.; Shai, Y. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. J. Mol. Biol., 2006, 364 (5), 1103-1117.
53. Markosyan, R. M.; Cohen, F. S.; Melikyan, G. B. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol. Biol. Cell, 2003, 14 (3), 926-938.
54. Teissier, E.; Penin, F.; Pecheur, E. I. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules, 2011, 16 (1), 221-250.
55. Watson, D. S.; Szoka, F. C. Jr. Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. Vaccine, 2009, 27 (34), 4672-4683.
56. White, J. M.; Delos, S. E.; Brecher, M.; Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol., 2008, 43 (3), 189-219.
57. Paskaleva, E. E.; Xue, J.; Lee, D. Y.; Shekhtman, A.; Canki, M. Palmitic acid analogs exhibit nanomolar binding affinity for the HIV-1 CD4 receptor and nanomolar inhibition of gp120-to-CD4 fusion. PLoS One, 2010, 5 (8), e12168.
58. Lee, D. Y.; Lin, X.; Paskaleva, E. E.; Liu, Y.; Puttamadappa, S. S.; Thornber, C.; Drake, J. R.; Habulin, M.; Shekhtman, A.; Canki, M. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection. AIDS Res. Hum. Retroviruses, 2009, 25 (12), 1231-1241.
59. Vaillant, A.; Juteau, J. M.; Lu, H.; Liu, S.; Lackman-Smith, C.; Ptak, R.; Jiang, S. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother., 2006, 50 (4), 1393-1401.
60. Bernstein, D. I.; Goyette, N.; Cardin, R.; Kern, E. R.; Boivin, G.; Ireland, J.; Juteau, J. M.; Vaillant, A. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob. Agents Chemother., 2008, 52 (8), 2727-2733.
61. Matsumura, T.; Hu, Z.; Kato, T.; Dreux, M.; Zhang, Y. Y.; Imamura, M.; Hiraga, N.; Juteau, J. M.; Cosset, F. L.; Chayama, K.; Vaillant, A.; Liang, T. J. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology, 2009, 137 (2), 673-681.
62. Cardin, R. D.; Bravo, F. J.; Sewell, A. P.; Cummins, J.; Flamand, L.; Juteau, J. M.; Bernstein, D. I.; Vaillant, A. Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virol. J., 2009, 6, 214.
63. Neurath, A. R.; Strick, N.; Jiang, S.; Li, Y. Y.; Debnath, A. K. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of dead-end gp41 six-helix bundles. BMC Infect. Dis., 2002, 2, 6.
64. Neurath, A. R.; Strick, N.; Li, Y. Y. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect. Dis., 2002, 2, 27-37.
65. Lu, H.; Zhao, Q.; Wallace, G.; Liu, S.; He, Y.; Shattock, R.; Neurath, A. R.; Jiang, B. S. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. Aids Res. Human Retroviruses, 2006, 22 (5), 411-418.
66. Liu, S.; Lu, H.; Neurath, A. R.; Jiang, S. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother., 2005, 49 (5), 1830-1836.
67. Krebs, F. C.; Miller, S. R.; Catalone, B. J.; Welsh, P. A.; Malamud, D.; Howett, M. K.; Wigdahl, B. Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes. Antimicrob. Agents Chemother., 2000, 44 (7), 1954-1960.
68. Madan, R. P.; Keller, M. J.; Herold, B. C. Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr. Opin. Infect. Dis., 2006, 19 (1), 49-54.
69. Balzarini, J.; Van Damme, L. Microbicide drug candidates to prevent HIV infection. Lancet, 2007, 369 (9563), 787-97.
70. Debnath, A. K.; Radigan, L.; Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem., 1999, 42 (17), 3203-3209.
71. Wang, H.; Qi, Z.; Guo, A.; Mao, Q.; Lu, H.; An, X.; Xia, C.; Li, X.; Debnath, A. K.; Wu, S.; Liu, S.; Jiang, S. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob. Agents Chemother., 2009, 53 (12), 4987-4998.
72. Cai, L.; Gochin, M. A Novel fluorescence intensity screening assay identifies new low molecular weight inhibitors of the gp41 coiled coil domain of HIV-1. Antimicrob. Agents Chemother., 2007, 51 (7), 2388-2395.
73. Naicker, K. P.; Jiang, S.; Lu, H.; Ni, J.; Boyer-Chatenet, L.; Wang, L.-X.; Debnath, A. K. Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives. Bioorg. Med. Chem., 2004, 12, 1215-1220.
74. Armand-Ugon, M.; Clotet-Codina, I.; Tintori, C.; Manetti, F.; Clotet, B.; Botta, M.; Este, J. A. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology, 2005, 343 (1), 141-149.
75. Liu, S.; Jiang, S.; Wu, Z.; Lv, L.; Zhang, J.; Zhu, Z.; Wu, S. Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte. Life Sci., 2002, 71 (15), 1779-1791.
76. Liu, S.; Lu, H.; Zhao, Q.; He, Y.; Niu, J.; Debnath, A. K.; Wu, S.; Jiang, S. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim. Biophys Acta, 2005, 1723 (1-3), 270-281.
77. Lu, L.; Liu, S. W.; Jiang, S. B.; Wu, S. G. Tannin inhibits HIV-1 entry by targeting gp41. Acta Pharmacol. Sin., 2004, 25 (2), 213-218.
78. Lee-Huang, S.; Huang, P. L.; Zhang, D.; Lee, J. W.; Bao, J.; Sun, Y.; Chang, Y. T.; Zhang, J.; Huang, P. L. Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. fusion [corrected] inhibition. Biochem. Biophys. Res. Commun., 2007, 354 (4), 872-878.
79. Bao, J.; Zhang, D. W.; Zhang, J. Z.; Huang, P. L.; Huang, P. L.; Lee-Huang, S. Computational study of bindings of olive leaf extract (OLE) to HIV-1 fusion protein gp41. FEBS Lett., 2007, 581 (14), 2737-2742.
80. Frazier, R. A.; Papadopoulou, A.; Mueller-Harvey, I.; Kissoon, D.; Green, R. J. Probing protein-tannin interactions by isothermal titration microcalorimetry. J. Agric. Food Chem., 2003, 51 (18), 5189-5195.
81. Mo, H.; Konstantinidis, A. K.; Stewart, K.; Dekhtyar, T.; Ng, T.; Swift, K.; Matayoshi, E.; Kati, W.; Kohlbrenner, W.; Molla, A. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology, 2004, 329 (2), 319-327.
82. Strockbine, B.; Rizzo, R. C. Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment. Proteins, 2007, 67 (3), 630-642.
83. Welch, B. D.; Francis, J. N.; Redman, J. S.; Paul, S.; Weinstock, M. T.; Reeves, J. D.; Lie, Y. S.; Whitby, F. G.; Eckert, D. M.; Hill, P.; Root, M. J.; Kay, M. S. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol., 2010, 84 (21), 11235-11244.
84. Welch, B. D.; VanDemark, A. P.; Heroux, A.; Hill, C. P.; Kay, M. S. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA, 2007, 104 (43), 16828-16833.
85. Eckert, D. M.; Malashkevich, V. N.; Hong, L. H.; Carr, P. A.; Kim, P. S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999, 99 (1), 103-115.
86. Liu, K.; Lu, H.; Hou, L.; Qi, Z.; Teixeira, C.; Barbault, F.; Fan, B. T.; Liu, S.; Jiang, S.; Xie, L. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J. Med. Chem., 2008, 51 (24), 7843-7854.
87. Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41. J. Am. Chem. Soc., 2009, 131 (8), 2821-2823.
88. Jiang, S.; Debnath, A. K.; Lu, H. Antiviral compositions comprising heterocyclic substituted phenyl furans and related compounds. WO 2006/138118, 2006.
89. Zhou, G.; Wu, D.; Hermel, E.; Balogh, E.; Gochin, M. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41. Bioorg. Med. Chem. Lett., 2010, 20 (5), 1500-1503.
90. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-Substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors. Antimicrob. Agents Chemother., 2004, 48 (11), 4349-4359.
91. Zhou, G, Wu, D, Snyder, B, Ptak, R.G, Kaur, H, Gochin, M. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41. J. Med. Chem., 2011 Sep 19. [Epub ahead of print]
92. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. J. Med. Chem., 2009, 52 (23), 7631-7639.
93. Stewart, K. D.; Huth, J. R.; Ng, T. I.; McDaniel, K.; Hutchinson, R. N.; Stoll, V. S.; Mendoza, R. R.; Matayoshi, E. D.; Carrick, R.; Mo, H.; Severin, J.; Walter, K.; Richardson, P. L.; Barrett, L. W.; Meadows, R.; Anderson, S.; Kohlbrenner, W.; Maring, C.; Kempf, J.; Molla, A.; Olejniczak, E. T. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket. Bioorg. Med. Chem. Lett., 2010, 20 (2), 612-617.
94. Frey, G, Rits Volloch, S, Zhang, X. Q, Schooley, R. T, Chen, B, Harrison, S. C. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. Acad. Sci. USA, 2006, 103 (38), 13938-13943.
95. Xu, Y.; Lu, H.; Kennedy, J. P.; Yan, X.; McAllister, L. A.; Yamamoto, N.; Moss, J. A.; Boldt, G. E.; Jiang, S.; Janda, K. D. Evaluation of credit card libraries for inhibition of HIV-1 gp41 fusogenic core formation. J. Comb. Chem., 2006, 8 (4), 531-539.
96. Jiang, S.; Tala, S. R.; Lu, H.; Abo-Dya, N. E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A. R.; Debnath, A. K. Design, synthesis, and biological activity of novel 5-((Arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phe nyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41. J. Med. Chem., 2011, 54 (2), 572-579.
97. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem. Int. Ed. Engl., 2002, 41 (2), 278-281.
98. Jun Tan, J.; Kong, R.; Xin Wang, C.; Zu Chen, W. Prediction of the binding model of HIV-1 gp41 with small molecule inhibitors. Conf. Proc. IEEE Eng. Med. Biol. Soc., 2005, 5, 4755-4758.
99. Mayaux, J.-F.; Bousseau, A.; Pauwels, R.; Huet, T.; Henin, Y.; Dereu, N.; Evers, M.; Soler, F.; Poujade, C.; De Clercq, E.; Le Pecq, J.-B. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc. Natl. Acad. Sci., 1994, 91, 3564-3568.
100. Labrosse, B.; Pleskoff, O.; Sol, N.; Jones, C.; Hénin, Y.; Alizon, M. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J. Virol., 1997, 71 (11), 8230-8236.
101. Murray, E. J.; Leaman, D. P.; Pawa, N.; Perkins, H.; Pickford, C.; Perros, M.; Zwick, M. B.; Butler, S. L. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J. Virol., 2010, 84 (14), 7288-7299.
102. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature, 2007, 450 (7172), 1001-1009.
103. Berg, T. Small-molecule inhibitors of protein-protein interactions. Curr. Opin. Drug Discov. Devel., 2008, 11 (5), 666-674.
104. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 1996, 274 (5292), 1531-1534.
105. Hajduk, P. J. Fragment-based drug design: how big is too big? J. Med. Chem., 2006, 49 (24), 6972-6976.
106. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov., 2004, 3 (4), 301-317.
107. Gochin, M.; Zhou, G.; Phillips, A. H. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket. ACS Chem. Biol., 2010, in press.
108. Berman, H.; Henrick, K.; Nakamura, H. Announcing the worldwide Protein Data Bank (www.pdb.org). Nat. Struct. Biol., 2003, 10 (12), 980.
109. Buzon, V.; Natrajan, G.; Schibli, D.; Campelo, F.; Kozlov, M. M.; Weissenhorn, W. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog., 2010, 6 (5), e1000880.
110. McGillick, B. E.; Balius, T. E.; Mukherjee, S.; Rizzo, R. C. Origins of resistance to the HIVgp41 viral entry inhibitor T20. Biochemistry (Mosc), 2010, 49 (17), 3575-3592.
111. Sackett, K.; Wexler-Cohen, Y.; Shai, Y. Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J. Biol. Chem., 2006, 281 (31), 21755-21762.
112. Liu, S.; Boyer-Chatenet, L.; Lu, H.; Jiang, S. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41. J. Biomol. Screen, 2003, 8 (6), 685-693.
113. Sun, W.; Wang, H. T.; Xia, C. L.; Wu, S. G.; Jiang, S. B.; Jiang, Z. H.; Liu, S. W. [1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane]. Nan Fang Yi Ke Da Xue Xue Bao, 2008, 28 (7), 1127-1131.